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Introduction
Few genes (RYR1, NEB, ACTA1, CFL2, KBTBD13) have
been associated with core-rod congenital myopathies [7].
KBTBD13 belongs to the Kelch-repeat super-family of
proteins and is implicated in the ubiquitination pathway.
Dominant mutations in KBTBD13 have been associated
with a peculiar form of core-rod myopathy (NEM6) so
far [10]. Childhood onset, slowly progressive proximal
muscle weakness with characteristic slowness of move-
ments and combination of nemaline rods, irregular
shaped cores and unusual type2 fibres hypotrophy at
muscle biopsy, were the main characteristics shared in
all the affected members of the four KBTBD13 families
reported in the literature [12].
We report on a 65 years old patient, of Sardinian origin,
with atypical clinical and morphological presentation of
NEM6 due to a novel mutation in KBTBD13 gene.
Methods
Patient underwent a complete clinical examination, car-
diac and respiratory evaluation, biological screening for
myopathies, muscle imaging studies, muscle biopsies
and molecular analysis for muscle diseases.
Morphological study
Three open muscle biopsies were obtained from deltoid,
paraspinal and quadriceps muscles. Sampling site was
based on neuroimaging study. For conventional
histochemical techniques 8 μm thick cryostat sections
were stained with haematoxylin and eosin (HE), modified
Gomori trichrome (GT), Periodic acid Schiff technique
(PAS), Oil red O, reduced nicotinamide adenine dinucleo-
tide dehydrogenase-tetrazolium reductase (NADH-TR),
succinic dehydrogenase (SDH), cytochrome c oxidase
(COX), and adenosine triphosphatase (ATPase) preincu-
bated at pH 9.4, 4.63, 4.35. Frozen muscle samples for im-
munohistochemical analysis were analysed for membrane
proteins study including antibodies against dystrophin
(N-ter, Rod, C-ter), sarcoglycans, α-dystroglycan (IIH6,
VIA4), laminin α2, dysferlin and caveolin-3. Antibodies
were visualized using innunoperoxidase techniques. Im-
munofluorescence study was performed for KBTBD13
with rabbit polyclonal antibodies (ab110507 abcam 1:50).
Ultrastructural study by electron microscopy (EM) was
performed on small muscle specimens from the last bi-
opsy, fixed with glutaraldehyde (2.5%, pH 7.4), post fixed
with osmium tetroxide (2%), dehydrated and embedded in
resin. Ultra-thin sections from 6 blocks small blocks were
stained with uranyl acetate and lead citrate. The grids
were observed using a Philips CM120 electron microscope
(80 kV; Philips Electronics NV, Eindhoven, The
Netherlands) and were photo documented using a Morada
camera (Soft Imaging System).
Neuroimaging study
Whole body CT-scan and lower limb muscle MRI were
obtained following a previously described protocol ac-
cording to international consensus recommendation [6].
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Western blot (WB) study
Skeletal muscle of patient and age-matched control
muscle specimens were isolated and snap frozen in liquid
nitrogen. Tissue lysates were prepared on ice in specific
buffer (50 mM Tris–HCl, pH 7.4, 150 mM NaCl, 1 mM
EDTA, 1% Triton X-100 or 1% NP40, 1 mM PMSF), and
protease inhibitor mixture. Lysates were cleared by centri-
fugation at 15000×g. Protein concentrations of the cleared
lysates were determined by BCA protein assay kit
(Thermo Fisher Scientific). Proteins (40 μg) were sepa-
rated by SDS-PAGE, loaded in a 4–12% denaturing gel,
transferred to Immobilon-P membrane and probed with
rabbit polyclonal against KBTBD13 (ab110507 abcam
1:500) and beta-tubulin (sigma 1:1000). Reactive bands
were detected using Lite Ablot Extend Long Lasting
Chemiluminescent Substrate (Euroclone, Pero, Italy).
Densitometry analysis was performed using Quantity One
software (BioRad, Hercules, CA, USA).
Molecular analysis
Next Generation Sequencing (NGS) was performed by a
customized gene panel including the following 95 genes:
NEB, MYO18B, ACTA1, TPM2, TPM3, KBTBD13,
KLHL40, KLHL41, LMOD3, TNNT1, CFL2, DNM2,
MTM1, SPEG1, CCDC78, BIN1, RYR1, MYH2, MYH7,
SEPN1, STIM1, ORAI1, PGAM2, MEGF10, MTMR14,
TRIM32, FHL1, HACD1, C-term TTN, VMA21, SCN4A,
CLCN1, VCP, GNE, KLHL9, HSPB8, ADSSL1, SQSTM1,
MATR3, TIA1, BAG3, CRYAB, DES, FLNC, LDB3 (ZASP),
HNRPDL, LMNA, FKRP, DYSF, CAPN3, FKTN, TOR1-
AIP1, GTDC2 (POMGNT2), GMPPB, LAMA2, COL6A1,
COL6A2, COL6A3, ANO5, PYGM, CPT2, CAV3, DMD,
EMD, CHKB, POMT1, POMT2, POMGNT1, FCMD,
LARGE, B3GALNT2, B4GAT1 (B3GNT1), COL4A1,
DAG1, ISPD, POMK (SGK196), TMEM5, SGCG, SGCA,
SGCB, SGCD, DNAJB6, MYOT, TNPO3, TCAP, RAPSN,
MUSK, DOK7, LAMB2, COLQ, GFPT1, CHRNE,
DPAGT1, CHAT, SMN1. Target enrichment was carried
out using Nextera Rapid Capture Custom Enrichment Kit
(Illumina, San Diego, California, USA) with probe design
by using the Design Studio software. Paired-end sequen-
cing was performed using an Illumina MiSeq with a se-
quencing depth of 100×. The Illumina VariantStudio data
analysis software was used to annotate the variants. Sanger
sequencing was used for POGLUT1 gene screening and
validation of KBTBD13 variant.
Molecular cloning
The pCMV6-AC-GFP mammalian expression vector
with subcloned wild type Human KBTBD13 cDNA
(kindly donated by Dr.Nyamkhishig Sambuughin of
Department of Military and Emergency Medicine,
Uniformed Services University, Bethesda, USA) was used
as the template DNA for producing the KBTBD13G67R
variant by exploiting the QuikChange XL site-directed
mutagenesis kit (Agilent Technologies). Specifically, the
substitution was performed by PCR amplification using
the following synthetic primers carrying the desired mu-
tation G67RF-5′-ctg cag gtg ctg cgc cgc gac cgg ccg gcg
ctg-3′ and G67RR-5′-cag cgc cgg ccg gtc gcg gcg cag
cac ctg cag-3′. The right insertion of the mutation was
then confirmed by DNA sequencing. Plasmidic DNA
was obtained by using NucleoBond Xtra (Macherey-Na-
gel, Duren, Germany). Then, HeLa were transfected by
using Lipofectamine 3000 (ThermoFisher Scientific,
Waltham, MA, USA) and plasmidic DNA (1000 ng), fol-
lowing manufacturer’s instructions.
Cell culture, transfection and fluorescence microscopy
HeLa cells were cultured in Dulbecco’s Modified Eagle
Medium (DMEM) supplemented with 10% foetal bovine
serum (FBS) and 50 μg/ml gentamycin. Cells were main-
tained in 5% CO2 atmosphere at 37 °C. All reagents for
cell culture were from ThermoFisher Scientific (Waltham,
MA, USA). HeLa cells were seeded at 21 × 105 cells/well
in 6-well plates 24 h prior transfection, and transfected by
using Lipofectamine 3000 (ThermoFisher Scientific), ac-
cording to manufacturer’s instructions. Cells were incu-
bated for 48 h, fixed with 4% paraformaldehyde
(Sigma-Aldrich), and viewed by using a confocal micros-
copy (Leica, Wetzlar, Germany).
Molecular modelling
The structure of KBTBD13 protein has yet to be deter-
mined experimentally but structural data are available for
other BTB-containing proteins, in some cases belonging
to the BTB-Kelch family. We used Homology Modelling
using SWISS-MODEL [1] to predict the structure of the
BTB domain only of WT KBTBD13. Since the BTB do-
main is known to be directly involved in the formation of
Kelch proteins dimers, we calculated the putative structure
of the dimer formed by the BTB domains of KBTBD13,
using as template the crystal structure that of the dimeric
BTB domain in SPOP:Cul3 assembly (3HQI.pdb). The
structure of the G67R mutant was also calculated by
Homolgy Modelling. The electrostatic potential was calcu-
lated using the APBS software [2] and the input file re-
quired to run APBS was prepared using PDB2PQR [5] on
the calculated WTand mutant protein structure.
Results
Clinical findings
The patient was born after uneventful pregnancy from
healthy non-consanguineous parents. He had a
71-years-old brother with muscle hypertrophy and late
onset gait disturbances who refused to be examined and
tested for biological and molecular analysis. Motor mile-
stones were normally acquired. He started to complain
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about slowly progressive muscular weakness of upper
and lower limbs since the age of 50. First clinical exam-
ination at the age of 60 revealed generalised muscle
hypertrophy, slowness of movements conferring a
slow-motion bearing, proximal upper and lower limb
weakness sparing distal muscles, Gowers’ sign and wad-
dling gait (Fig. 1a). He had moderate respiratory involve-
ment (FVC 69%) with normal cardiac evaluation.
Electromyography (EMG) showed myopathic changes,
and Creatine-Kinase (CK) ranged between 250 and 350
UI/L (normal values < 180 UI/L).
Muscle imaging data
Whole body muscle CT scan performed at 60 years
showed a moderate to severe fibro-fatty replacement in
deltoids, subscapularis and infraspinatus, serratus, latis-
simus dorsi, cervical paraspinalis and rectus abdominis,
iliopsoas, tensor fascia lata and gluteus maximus with
sparing of leg muscles. Interestingly, several muscles
presented an irregular pattern of fibro-fatty replacement.
A peculiar pattern involving the internal regions and
sparing the external areas (“from inside-to-outside”) was
observed in thigh muscles (Fig. 1b). Moreover, rectus
femoris presented the “central shadow” sign and gluteus
maximus showed a “zebra” pattern of fibro-fatty replace-
ment, characterized by consecutive strips of replaced
and spared muscle tissue.
Morphological features
The first muscle biopsy, performed in deltoid muscle at
60 years, showed fibre size variability and splitting with
type1 predominance. Small clusters of subsarcolemmal
rods were detected in less than 5% of muscle fibres
(Fig. 1c); immunohistochemistry for membrane pro-
teins was normal. The second muscle biopsy was per-
formed in paraspinal muscles at the age of 61, obtained
during spinal surgery because of acute lumbar disc her-
niation, and showed subsarcolemmal and cytoplasmic
rods in several fibres (~ 30%), type1 fibre uniformity
and irregular areas of myofibrillar disorganization,
sometimes resembling cores (Fig. 1d,). The third
muscle biopsy performed on the quadriceps muscle at
65 years, clearly showed the presence of classic eccen-
tric cores in some fibres (< 10%) (Fig. 2a, b, c), fibre size
variability and splitting, type1 uniformity and abundant
lobulated fibres with irregular myofibrillar network at
oxidative stains (Fig. 2c). Ultrastructural study of the
last biopsy confirmed the presence of cores with
abundant electrodense longitudinally smeared material
(Fig. 2d, e) and detected small nemaline rods in atro-
phic fibres (Fig. 2f ). Areas of Z-line smearing and thick-
ening were also observed outside cores (Fig. 2g, h).
Protein aggregates were not detected.
Molecular data
NGS allowed to identify a novel heterozygous c.199G > C
(p.Gly67Arg) mutation in the BTB/POZ domain of
KBTBD13 gene (Fig. 3a). Other 94 genes included in the
panel were ruled. The G67R variant falls in highly con-
served protein domain with MAF < 0.0001 (genomAD
Database) and is predicted to be pathogenetic by bioinfor-
matic software.
Structural and functional investigations
Transfected HeLa cells with KBTBD13G67R and
KBTBD13wt vectors did not show any difference in cellular
expression or localization of KBTBD13 (Fig. 3,C). Interest-
ingly, we observed a reduction of 48.3% of the KBTBD13
expression by WB on patient’s muscle biopsy compared to
healthy controls (Fig. 3b). Finally, molecular modelling of
KBTBD13 protein showed that residue 67 is very close to
the BTB dimerization interface and the Gly-to-Arg substi-
tution impacts on a wide area of surface electrostatic po-
tential around the residue 67 (Fig. 3d).
Discussion
Although some clinical features were quite similar to
those previously described in KBTBD13 patients, as the
characteristic slowness of movements, the late age at on-
set in our patient represents a novel insight for
KBTBD13-related myopathy, since all the previously re-
ported patients manifested a childhood onset. Moreover,
our patient showed unusual LGMD-like clinical pheno-
type characterized by waddling gait and muscle hyper-
trophy. Muscle MRI findings were different from those
previously reported in KBTBD13 patients and surpris-
ingly, the peculiar “from inside-to outside” pattern of
fibro-fatty replacement was very similar to what has
been recently described in POGLUT1 muscular dys-
trophy [13]. For this reason, we also ruled out possible
mutations in POGLUT1 gene by Sanger analysis. The
“central shadow” sign of the rectus femoris has been de-
scribed in COL6-related myopathies, but contrary to the
“inside-to-outside” pattern observed in our patient,
COL6 myopathies show a typical peripheral involvement
of thigh muscles [8]. Moreover, the full preservation of
lower leg muscles observed in our patient could help in
differential diagnosis with both COL6 and
POGLUT1-related myopathies which typically show so-
leus involvement. To the best of our knowledge, “zebra”
pattern of gluteus maximus has never been reported in
other myopathies.
Concerning morphology, nemaline rods were con-
stantly observed in all muscle biopsies performed in our
patient, although sometimes detected only in few fibres
or just by EM study. Only the third muscle biopsy re-
vealed sharply demarked cores, never detected in previ-
ous reports, whereas the second one showed
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irregular-shaped areas devoid oxidative stains as de-
scribed in previously cases. Interestingly, none of the bi-
opsies showed the type2 fibre hypotrophy previously
described in all reported KBTBD13 patients. Congenital
myopathies are frequently characterised by prevalence/
uniformity of type1 fibres, most of which are hypo-
trophic, and sometimes could manifest as Congenital
Fibre Type Disproportion (CFTD), characterised by
marked hypotrophy of all type1 fibres mixed with nor-
mal type2 fibres [4]. Conversely, type 2 hypotrophy rep-
resent an uncommon finding among congenital
myopathies, and more broadly among inherited myop-
athies. Type2 atrophy is frequently observed in acquired
conditions as cachexia, aging or corticosteroid-induced
myopathy [3], and among inherited myopathies it has
been rarely reported [9]. Among congenital myopathies
and particularly nemaline myopathies, the type2 hypo-
trophy has been described only in KBTBD13 and repre-
sented a specific signature of NEM6. Conversely, our
patient showed type1 prevalence or uniformity, as com-
monly observed in many congenital myopathies.
The clinical and histological variability observed in our
patient compared to the previously reported NEM6 pa-
tients, could be related to the different localization of
the KBTBD13 mutation. In fact, all the three mutations
previously reported are located in Kelch domain,
whereas G67R mutation detected in our patient is in the
BTB/POZ domain. Possibly, the surprising reduction of
KBTBD13 protein by WB analysis might be explained
considering the effect of G67R mutation. KBTBD13
(See figure on previous page.)
Fig. 1 Clinical and histological findings. Picture of the patient (a): note the generalized muscle hypertrophy. Whole body muscle CT scan (b):
characteristic “inside-to outside” involvement of the thighs (box); zebra pattern (arrows) of gluteus maximus; “central shadow” of rectus femoris
(arrowheads); fibro-fatty replacement is also present in deltoids, subscapularis and infraspinatus, serratus, latissimus dorsi, cervical paraspinalis and
rectus abdominis, iliopsoas, tensor fascia lata and gluteus maximus with while lower leg muscles are spared. Deltoid muscle biopsy at 60 years (c):
rare cluster of subsarcolemmal rods (GT) and prevalence and hypotrophy of type1 fibres (NADH). Paraspinal muscle biopsy at 61 years (d): several
fibres showing cytoplasmic and subsarcolemmal rods (GT) and irregular shaped areas devoid oxidative stain (COX/SDH)
Fig. 2 Histological and ultrastructural findings of the last muscle biopsy. Quadriceps muscle biopsy at 65 years. Sharply demarked cores in
seriated sections at GT (a) and NADH (b). Cores and lobulated fibres with irregular myofibrillar network at SDH (c). Electron microscopy findings:
cores containing abundant electrodense smeared material (d and e, asterisk); small rods (f,arrowheads); fragments of thickened Z-line (g); smaller
areas of sarcomeric disorganization with Z-line smearing (h)
Garibaldi et al. Acta Neuropathologica Communications  (2018) 6:94 Page 5 of 7
proteins assemble into dimers through self-association
of the BTB domains. Each BTB domain interacts with
the N-terminus of one Cul3 molecule forming a RING
ubiquitin ligase (Cul3-RL) complex capable of ubiquiti-
nation [11]. Our molecular modelling revealed that loca-
tion of Gly67 is very close to the BTB dimerization
interface; on the contrary, the location of residue 67 is
rather far from Cul3-binding interface. Since the muta-
tion described concerns the substitution of a small,
hydrophobic amino acid (Gly) with another featuring a
rather bulky side chain, positively charged at physio-
logical pH (Arg), it is likely that the mutation alters the
surface properties of the protein, especially the surface
electrostatic potential. Electrostatic interactions across
protein interfaces are known to be crucial to the forma-
tion of multimers and complexes that often represent
the biologically active conformation of proteins. Our
computational investigations also suggest that the G67R
Fig. 3 Schematic view of KBTBD13 and functional essays. Schematic view of KBTBD13 transcript (a) showing BTB and Kelch-repeat domains. Kelch
domain is composed by five repeats. First and last aminoacidic residues of both domains are also reported. The novel G67R mutation (bold red)
in BTB domain and the three previously described mutations (dark blue) in Kelch domain. WB of KBTBD13 (b) showing the reduced protein
expression in patient’s muscle biopsy (pt) compared to healthy controls (ctrl). Representative confocal microscopy images of HeLa cells
transfected with KBTBD13WT and KBTBD13G67R pCMV6-AC-GFP plasmids. Nuclei were counterstained with 4,6-diamidino-2-phenylindole (DAPI).
Scale bars: 10 μm. No difference between wild type-KBTBD13 and G67R-KBTBD13 expression and localization in HeLa transfected cells (c).
Molecular models (D) of WT and mutated KBTBD13. In the upper left panel, interaction of two homodimer BTB domains (light blue and green,
respectively) of two KBTBD13 molecules (not shown) as obtained by molecular modelling. The protein backbone atoms are represented as
ribbons, while the two Gly67 side chains are shown as Van der Waals spheres and circled in red. The upper right panel displays the calculated model
of the complex between the BTB (green) and Cul3 (red). The protein backbone is represented as ribbons, and Gly67 side chain are shown as Van der
Waals spheres and circled in red. The calculated model suggests that the mutated residue lies far from the interaction interface with Cul3. The lower
panel on the left shows the structure of the predicted homodimer BTB-BTB (with the same size and orientation of the upper left panel) which is
coloured according to its calculated surface electrostatic potential. Regions of positive and negative electrostatic potential are shown in blue and red,
respectively, and the yellow asterisks indicate the position of residue 67 in both BTB domains forming the dimer. The lower panels on the right depict
the changes in the surface electrostatic potential of BTB domain when Gly67 (WT) is mutated in silico into Arg67 (G67R). Note the surface electrostatic
potential showing a marked loss of the surface negative potential (red colour) surrounding residue 67 in G67R mutant with respect to the WT
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mutation alters the surface electrostatic potential, prob-
ably impacting the tendency of BTB dimerization in vivo.
Nevertheless, this study concerns only one patient and
more evidences are needed to conclusively state the effect
of mutations in BTB/POZ domain of KBTBD13 gene.
Conclusions
In conclusion our findings broaden the clinical, histo-
logical and genetical spectrum of the ultra-rare
KBTBD13-related myopathy and enlarge pathophysio-
logical knowledges about nemaline myopathies, showing
that NEM6 can have an adult onset, may show muscle
hypertrophy with peculiar “inside-to-outside” MRI/CT
pattern, and may lack of type2-hypotrophy at muscle bi-
opsy. Different domains involved of KBTBD13 could
lead to the phenotypic variability in NEM6.
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